Skip to main content
Erschienen in: Nuclear Medicine and Molecular Imaging 1/2019

18.12.2018 | Perspective

The Emergence of Theranostics in the Philippines: Overcoming Challenges and Bringing Hope

verfasst von: Patricia A. Bautista

Erschienen in: Nuclear Medicine and Molecular Imaging | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Medical managements are becoming personalized while diseases are being understood at the molecular level. Nuclear medicine is one of the fields actively contributing to this development. In particular, theranostics, a combinatorial term for therapy and diagnostics, enables accurate imaging and subsequent targeted radionuclide treatment. Due to its high impact in healthcare, many countries have begun to offer Ga-68 PET/CT scans and Lu-177 therapies. The Philippines has followed suit through the initiative of this author and able support of the administration and staff of St. Luke’s Medical Center. The Ga-68 DOTATATE and PSMA PET/CT scans became officially available in January 2018 while the first peptide receptor radionuclide therapy for neuroendocrine tumor and first PSMA radioligand therapy for prostate cancer occurred in May and June 2018, respectively. Amidst past, present, and future challenges, theranostics has emerged in the Philippines, offering hope to cancer patients in the country.
Literatur
1.
Zurück zum Zitat Herrmann K, Larson SM, Weber WA. Theranostic concepts: more than just a fashion trend – introduction and overview. J Nucl Med. 2017;58:1S–2S.CrossRefPubMed Herrmann K, Larson SM, Weber WA. Theranostic concepts: more than just a fashion trend – introduction and overview. J Nucl Med. 2017;58:1S–2S.CrossRefPubMed
2.
Zurück zum Zitat Sawin CT, Becker DV. Radioiodine and the treatment of hyperthyroidism: the early history. Thyroid. 1997;7(2):163–76.CrossRefPubMed Sawin CT, Becker DV. Radioiodine and the treatment of hyperthyroidism: the early history. Thyroid. 1997;7(2):163–76.CrossRefPubMed
3.
Zurück zum Zitat Hofmann M, Maecke H, Borner R, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med Mol Imaging. 2001;28:1751–7.CrossRef Hofmann M, Maecke H, Borner R, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med Mol Imaging. 2001;28:1751–7.CrossRef
4.
Zurück zum Zitat Rösch F, Baum RP. Generator-based PET radiopharmaceuticals for molecular imaging of tumours: on the way to theranostics. Dalton Trans. 2011;40:6104–11.CrossRefPubMed Rösch F, Baum RP. Generator-based PET radiopharmaceuticals for molecular imaging of tumours: on the way to theranostics. Dalton Trans. 2011;40:6104–11.CrossRefPubMed
5.
Zurück zum Zitat Baum RP, Kulkarni HR. Theranostics: from molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy – the Bad Berka experience. Theranostics. 2012;2(5):437–47.CrossRefPubMedCentralPubMed Baum RP, Kulkarni HR. Theranostics: from molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy – the Bad Berka experience. Theranostics. 2012;2(5):437–47.CrossRefPubMedCentralPubMed
6.
Zurück zum Zitat Bautista PA, San Luis TOL. Nuclear medicine in the Philippines: a glance at the past, a gaze at the present, and a glimpse of the future. Asia Ocean J Nucl Med Biol. 2016;4(2):113–8.PubMedCentralPubMed Bautista PA, San Luis TOL. Nuclear medicine in the Philippines: a glance at the past, a gaze at the present, and a glimpse of the future. Asia Ocean J Nucl Med Biol. 2016;4(2):113–8.PubMedCentralPubMed
7.
Zurück zum Zitat Zaknun JJ, Bodei L, Mueller-Brand J, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40(5):800–16.CrossRefPubMedCentralPubMed Zaknun JJ, Bodei L, Mueller-Brand J, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40(5):800–16.CrossRefPubMedCentralPubMed
8.
Zurück zum Zitat Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C. Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:471–95.CrossRefPubMed Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C. Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:471–95.CrossRefPubMed
Metadaten
Titel
The Emergence of Theranostics in the Philippines: Overcoming Challenges and Bringing Hope
verfasst von
Patricia A. Bautista
Publikationsdatum
18.12.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Nuclear Medicine and Molecular Imaging / Ausgabe 1/2019
Print ISSN: 1869-3474
Elektronische ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-018-0560-7

Weitere Artikel der Ausgabe 1/2019

Nuclear Medicine and Molecular Imaging 1/2019 Zur Ausgabe